RhBMP-2/alphaBSM induces significant vertical alveolar ridge augmentation and dental implant osseointegration

Ulf M E Wikesjö, Rachel G. Sorensen, Atsuhiro Kinoshita, John M. Wozney

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

BACKGROUND: Recombinant human bone morphogenetic protein 2 (rhBMP-2) in a carrier has been shown to induce significant bone formation. Several candidate carriers, however, lack structural integrity to offset compressive forces that may compromise rhBMP-2 bone induction, in particular, for challenging onlay indications such as alveolar ridge augmentation. PURPOSE: The objective of this study was to evaluate rhBMP-2 in a calcium-phosphate cement carrier, alphaBSM, for vertical alveolar ridge augmentation and immediate dental implant osseointegration. MATERIALS AND METHODS: Six adult Hound Labrador mongrels with 5 mm critical size supra-alveolar peri-implant defects were used. Three animals received rhBMP-2/alphaBSM (rhBMP-2 at 0.40 and 0.75 mg/mL) in contralateral jaw quadrants (total implant volume/defect approximately 1.5 mL). Three animals received alphaBSM without rhBMP-2 (control group). The animals were euthanized at 16 weeks post surgery, and block biopsies were processed for histologic and histometric analysis. RESULTS: rhBMP-2/alphaBSM induced substantial augmentation of the alveolar ridge. Control sites exhibited limited new bone formation. Vertical bone augmentation averaged (+/- SD) 4.9 +/- 1.0 mm (rhBMP-2 at 0.40 mg/mL), 5.3 +/- 0.3 mm (rhBMP-2 at 0.75 mg/mL), and 0.4 +/- 0.4 mm (control); new bone area 8.5 +/- 4.2 mm2, 9.0 +/- 1.9 mm2, and 0.5 +/- 0.4 mm2; new bone density 55.1 +/- 6.4%, 61.1 +/- 6.0%, and 67.7 +/- 9.5%; and new bone-implant contact 26.9 +/- 17.5%, 28.5 +/- 1.4%, and 24.6 +/- 16.1%, respectively. Residual alphaBSM comprised < 1% of the new bone. Bone density for the contiguous resident bone ranged from 65 to 71%, and bone-implant contact ranged from 49 to 64%. CONCLUSIONS: Surgical implantation of rhBMP-2/alphaBSM appears an effective protocol for vertical alveolar ridge augmentation procedures and immediate dental implant osseointegration and for onlay indications of lesser complexity.

Original languageEnglish (US)
Pages (from-to)174-182
Number of pages9
JournalClinical implant dentistry and related research
Volume4
Issue number4
DOIs
StatePublished - Jan 1 2002

Fingerprint

Alveolar Ridge Augmentation
Osseointegration
Dental Implants
Bone and Bones
Inlays
Osteogenesis
Bone Density
recombinant human bone morphogenetic protein-2
Newfoundland and Labrador
Jaw

ASJC Scopus subject areas

  • Oral Surgery
  • Dentistry(all)

Cite this

RhBMP-2/alphaBSM induces significant vertical alveolar ridge augmentation and dental implant osseointegration. / Wikesjö, Ulf M E; Sorensen, Rachel G.; Kinoshita, Atsuhiro; Wozney, John M.

In: Clinical implant dentistry and related research, Vol. 4, No. 4, 01.01.2002, p. 174-182.

Research output: Contribution to journalArticle

Wikesjö, Ulf M E ; Sorensen, Rachel G. ; Kinoshita, Atsuhiro ; Wozney, John M. / RhBMP-2/alphaBSM induces significant vertical alveolar ridge augmentation and dental implant osseointegration. In: Clinical implant dentistry and related research. 2002 ; Vol. 4, No. 4. pp. 174-182.
@article{4bbefb76dfb94fa2aacdc09012941f1d,
title = "RhBMP-2/alphaBSM induces significant vertical alveolar ridge augmentation and dental implant osseointegration",
abstract = "BACKGROUND: Recombinant human bone morphogenetic protein 2 (rhBMP-2) in a carrier has been shown to induce significant bone formation. Several candidate carriers, however, lack structural integrity to offset compressive forces that may compromise rhBMP-2 bone induction, in particular, for challenging onlay indications such as alveolar ridge augmentation. PURPOSE: The objective of this study was to evaluate rhBMP-2 in a calcium-phosphate cement carrier, alphaBSM, for vertical alveolar ridge augmentation and immediate dental implant osseointegration. MATERIALS AND METHODS: Six adult Hound Labrador mongrels with 5 mm critical size supra-alveolar peri-implant defects were used. Three animals received rhBMP-2/alphaBSM (rhBMP-2 at 0.40 and 0.75 mg/mL) in contralateral jaw quadrants (total implant volume/defect approximately 1.5 mL). Three animals received alphaBSM without rhBMP-2 (control group). The animals were euthanized at 16 weeks post surgery, and block biopsies were processed for histologic and histometric analysis. RESULTS: rhBMP-2/alphaBSM induced substantial augmentation of the alveolar ridge. Control sites exhibited limited new bone formation. Vertical bone augmentation averaged (+/- SD) 4.9 +/- 1.0 mm (rhBMP-2 at 0.40 mg/mL), 5.3 +/- 0.3 mm (rhBMP-2 at 0.75 mg/mL), and 0.4 +/- 0.4 mm (control); new bone area 8.5 +/- 4.2 mm2, 9.0 +/- 1.9 mm2, and 0.5 +/- 0.4 mm2; new bone density 55.1 +/- 6.4{\%}, 61.1 +/- 6.0{\%}, and 67.7 +/- 9.5{\%}; and new bone-implant contact 26.9 +/- 17.5{\%}, 28.5 +/- 1.4{\%}, and 24.6 +/- 16.1{\%}, respectively. Residual alphaBSM comprised < 1{\%} of the new bone. Bone density for the contiguous resident bone ranged from 65 to 71{\%}, and bone-implant contact ranged from 49 to 64{\%}. CONCLUSIONS: Surgical implantation of rhBMP-2/alphaBSM appears an effective protocol for vertical alveolar ridge augmentation procedures and immediate dental implant osseointegration and for onlay indications of lesser complexity.",
author = "Wikesj{\"o}, {Ulf M E} and Sorensen, {Rachel G.} and Atsuhiro Kinoshita and Wozney, {John M.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1111/j.1708-8208.2002.tb00169.x",
language = "English (US)",
volume = "4",
pages = "174--182",
journal = "Clinical Implant Dentistry and Related Research",
issn = "1523-0899",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - RhBMP-2/alphaBSM induces significant vertical alveolar ridge augmentation and dental implant osseointegration

AU - Wikesjö, Ulf M E

AU - Sorensen, Rachel G.

AU - Kinoshita, Atsuhiro

AU - Wozney, John M.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - BACKGROUND: Recombinant human bone morphogenetic protein 2 (rhBMP-2) in a carrier has been shown to induce significant bone formation. Several candidate carriers, however, lack structural integrity to offset compressive forces that may compromise rhBMP-2 bone induction, in particular, for challenging onlay indications such as alveolar ridge augmentation. PURPOSE: The objective of this study was to evaluate rhBMP-2 in a calcium-phosphate cement carrier, alphaBSM, for vertical alveolar ridge augmentation and immediate dental implant osseointegration. MATERIALS AND METHODS: Six adult Hound Labrador mongrels with 5 mm critical size supra-alveolar peri-implant defects were used. Three animals received rhBMP-2/alphaBSM (rhBMP-2 at 0.40 and 0.75 mg/mL) in contralateral jaw quadrants (total implant volume/defect approximately 1.5 mL). Three animals received alphaBSM without rhBMP-2 (control group). The animals were euthanized at 16 weeks post surgery, and block biopsies were processed for histologic and histometric analysis. RESULTS: rhBMP-2/alphaBSM induced substantial augmentation of the alveolar ridge. Control sites exhibited limited new bone formation. Vertical bone augmentation averaged (+/- SD) 4.9 +/- 1.0 mm (rhBMP-2 at 0.40 mg/mL), 5.3 +/- 0.3 mm (rhBMP-2 at 0.75 mg/mL), and 0.4 +/- 0.4 mm (control); new bone area 8.5 +/- 4.2 mm2, 9.0 +/- 1.9 mm2, and 0.5 +/- 0.4 mm2; new bone density 55.1 +/- 6.4%, 61.1 +/- 6.0%, and 67.7 +/- 9.5%; and new bone-implant contact 26.9 +/- 17.5%, 28.5 +/- 1.4%, and 24.6 +/- 16.1%, respectively. Residual alphaBSM comprised < 1% of the new bone. Bone density for the contiguous resident bone ranged from 65 to 71%, and bone-implant contact ranged from 49 to 64%. CONCLUSIONS: Surgical implantation of rhBMP-2/alphaBSM appears an effective protocol for vertical alveolar ridge augmentation procedures and immediate dental implant osseointegration and for onlay indications of lesser complexity.

AB - BACKGROUND: Recombinant human bone morphogenetic protein 2 (rhBMP-2) in a carrier has been shown to induce significant bone formation. Several candidate carriers, however, lack structural integrity to offset compressive forces that may compromise rhBMP-2 bone induction, in particular, for challenging onlay indications such as alveolar ridge augmentation. PURPOSE: The objective of this study was to evaluate rhBMP-2 in a calcium-phosphate cement carrier, alphaBSM, for vertical alveolar ridge augmentation and immediate dental implant osseointegration. MATERIALS AND METHODS: Six adult Hound Labrador mongrels with 5 mm critical size supra-alveolar peri-implant defects were used. Three animals received rhBMP-2/alphaBSM (rhBMP-2 at 0.40 and 0.75 mg/mL) in contralateral jaw quadrants (total implant volume/defect approximately 1.5 mL). Three animals received alphaBSM without rhBMP-2 (control group). The animals were euthanized at 16 weeks post surgery, and block biopsies were processed for histologic and histometric analysis. RESULTS: rhBMP-2/alphaBSM induced substantial augmentation of the alveolar ridge. Control sites exhibited limited new bone formation. Vertical bone augmentation averaged (+/- SD) 4.9 +/- 1.0 mm (rhBMP-2 at 0.40 mg/mL), 5.3 +/- 0.3 mm (rhBMP-2 at 0.75 mg/mL), and 0.4 +/- 0.4 mm (control); new bone area 8.5 +/- 4.2 mm2, 9.0 +/- 1.9 mm2, and 0.5 +/- 0.4 mm2; new bone density 55.1 +/- 6.4%, 61.1 +/- 6.0%, and 67.7 +/- 9.5%; and new bone-implant contact 26.9 +/- 17.5%, 28.5 +/- 1.4%, and 24.6 +/- 16.1%, respectively. Residual alphaBSM comprised < 1% of the new bone. Bone density for the contiguous resident bone ranged from 65 to 71%, and bone-implant contact ranged from 49 to 64%. CONCLUSIONS: Surgical implantation of rhBMP-2/alphaBSM appears an effective protocol for vertical alveolar ridge augmentation procedures and immediate dental implant osseointegration and for onlay indications of lesser complexity.

UR - http://www.scopus.com/inward/record.url?scp=0038519784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038519784&partnerID=8YFLogxK

U2 - 10.1111/j.1708-8208.2002.tb00169.x

DO - 10.1111/j.1708-8208.2002.tb00169.x

M3 - Article

C2 - 12685792

AN - SCOPUS:0038519784

VL - 4

SP - 174

EP - 182

JO - Clinical Implant Dentistry and Related Research

JF - Clinical Implant Dentistry and Related Research

SN - 1523-0899

IS - 4

ER -